Company profile
Resverlogix Corp.
OTC: RVXCF · Healthcare · Biotechnology
Canadian filerHQ Calgary, ABReports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH 19DQ —GM —SS 54
v0.1 · 35/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ balance-sheet leverage, Altman-Z
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$7.9M
Employees
19
as of 2026-08-21
Market cap
$25.4M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$7.9M-$7.9M2025
Operating income-$5.2M-$5.2M2025
Total assets$7.9M$7.9M2025
Liabilities$96.7M$96.7M2025
Equity-$88.8M-$88.8M2025
Revenue trend
FY2016 – FY2025 · USD
FY16
FY17
FY18
FY19
FY21
FY22
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Resverlogix Corp.’s revenue?
Resverlogix Corp. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
BeyondSpring Inc.34DSona Nanotech Inc.——Defence Therapeutics Inc.——EOM Pharmaceuticals Holdings, Inc.——Barinthus Biotherapeutics plc39DRein Therapeutics Inc.36DKey facts
CEODonald J. McCaffrey
SectorHealthcare
IndustryBiotechnology
HeadquartersCalgary, AB
ExchangeOTC: RVXCF
Employees19
IPO date2009-02-13
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.